Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Mallinckrodt has agreed to purchase Questcor Pharmaceuticals for $5.6 billion. The deal will add Questcor’s only commercial product, H.P. Acthar Gel, to Mallinckrodt’s menu of specialty drugs. Acthar, approved in the U.S. for 19 indications, many associated with autoimmune and inflammatory diseases, generated sales of $761 million last year, a 50% increase over 2012. Questcor CEO Don M. Bailey has been credited with growing the company with the help of huge price increases for Acthar and the development of new applications. Mallinckrodt will also take on a small contract manufacturing business as part of the deal. Last year, Questcor acquired BioVectra, the Canadian producer of Acthar’s active ingredient, for $50 million.
This article has been sent to the following recipient: